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Metastases to other organs and the formation of secondary tumors are responsible for 90% of cancer-related 
deaths. However, even in the early stages of cancer, about 30–40% of patients with localized disease may have latent 
metastasis, which are likely derived from circulating tumor cells (CTCs) involved in disease progression. Therefore, 
detection and analysis of CTCs can play an important role in the diagnosis and decision-making of adjuvant treat-
ment that aims to prevent metastasis. At present, patients’ selection of treatment is based on the statistical risk of 
recurrence of metastatic disease, without considering whether the tumor cells have spread from the primary tumor. 
This may lead to unnecessary treatment of non-metastatic disease patients. Therefore, early detection of CTCs in the 
blood is critically important, and should allow for a more accurate assessment of disease severity. Here, we provide 
an overview of CTC phenotypes, including plasticity of CTCs, and their clinical significance.
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Introduction
Circulating tumor cells (CTCs) have been detected in 
blood, and first described in 1896 by Thomas Ashworth [1]. 
CTCs are defined as circulating cells whose antigenic or 
genetic characteristics correspond to the characteristics of 
a specific tumor type. The presence of CTCs in the blood 
stream reflects the process of metastasis, as described by the 
theory of ‘seed and soil’ [2]. Under this definition, metastasis 
occurs when cancer cells are detached from the primary 
tumor and enter the bloodstream, moving in the direction 
of distant organs where they can settle and create a new 
focus i.e., a metastasis [2]. 
Together, metastasis and the formation of secondary 
tumors are responsible for 90% of deaths in cancer pa-
tients. However, even in the early stages of cancer, about 
30–40% of patients with localized disease may have latent 
metastases, potentially derived from CTCs involved in the 
progression of the disease [3, 4]. Therefore, detecting and 
analyzing CTCs may play an important role in the diagnosis 
and decision to provide adjuvant therapy. Patients have 
been hitherto selected based on the statistical risk of meta-
static relapse, without due consideration of whether cancer 
cells have spread from the primary tumor. This may result 
in unnecessary therapeutic treatment of patients without 
metastases and, consequently, serious side effects of such 
treatment. For this reason, early detection of CTCs is cri-
tically important, as this would allow for a more accurate 
assessment of the disease stage, and for monitoring effects 
of treatment. Compared to metastatic tissue biopsy, there 
are many advantages of isolating CTCs. For example, blood 
collection is easier, cheaper, less invasive for the patient, and 
can be repeated several times while tracking cancer treat-
ment. A blood sample containing CTCs is often referred to 
as a ‘liquid biopsy’, and may serve as a proxy for metastatic 
cancer [5]. In the future, liquid biopsy could be introduced 
for diagnostic screening, thus allowing for cancer to be 
monitored more easily via blood testing. 
The biology of metastasis
Metastatic colonization by CTCs is a complex process 
involving many steps, such as tissue invasion and intrava-
sation, survival in the bloodstream, extravasation, organ 
infiltration, colonization of a metastatic niche, and formation 
of macrometastasis (Fig. 1). 
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Table I. pCR rate within the lymph nodes after preoperative chemotherapy
Study N The rate of pCR in the 
lymph nodes 
ACOSOG Z1071 (cT0–4N1/2)
16 649 41%
SN FNAC (cT0–3N1/2)
17 145 35%
Mamtani (cT0–3N1/2)
18 195 49%
Figure 1. Metastatic cascade. A. Primary tumor secretes factors responsible for pre-metastatic niche formation at the distant site. This step 
facilitates subsequent tumor cell seeding by remodeling the composition of the extracellular matrix. B. Motile tumor cells (single cells and/or 
cell clusters) intravasate into circulation, where they become subjected to severe stress factors, including shear forces, lack of adhesion, immune 
reaction and oxidative stress. The influence of these factors can be modulated by platelets, which shield tumor cells from shear stress and immune 
attack. The lack of adhesion is compensated by either EMT or intracellular adhesion in case of CTC clusters. Subsequent extravasation into  
pre-metastatic niche allows for tumor cell survival and leads to either dormancy or proliferation and macrometastasis
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Parallel progression
Even small tumors at an early stage of advancement 
can shed cancer cells, which contradicts the conventional, 
linear model of cancer progression and dissemination [6]. In 
breast cancer, disseminated cancer cells (DCCs, also called 
DTCs, disseminated tumor cells) have been shown to contain 
fewer genetic alternations than primary cells, suggesting 
that they were seeded very early on and progressed sepa-
rately. This phenomenon is known as the ‘theory of parallel 
progression’, and poses important therapeutic problems, 
since cell dissemination occurs even before diagnosis [7]. 
Previous studies have shown that early DCCs are not as ef-
fective as late DCCs in the formation of primary tumors after 
implantation in the mammary fat pad. However, early DCCs 
are more metastasis-competent, and form more metastases 
and at a faster rate than late DCCs [6].
Early dissemination was demonstrated to depend on 
progesterone hormone signaling and abnormalities in the 
WNT signaling pathway [7]. As shown by Hosseini et al. [6], 
early DCCs have a different molecular signature than cells of 
the primary tumor. Further knowledge is needed to unveil 
the trigger mechanisms of early dissemination, which will 
be critical to future schemes of prevention and treatment. 
Routes of invasion
For early or late cancer cells to disseminate, several vital 
problems need to be resolved; one of these problems invo-
lves efficient migration into the circulatory system.
The first step in the metastatic cascade is an invasion 
of surrounding tissues, which usually coincides with de-
gradation of the stroma, activation of the immune system, 
and generation of cancer associated fibroblasts (CAFs) and 
the reactive stroma. These create a microenvironment that 
supports migration and cancer cell invasion. Cell migration 
can take many forms, such as the migration of single cells 
secreting extracellular-matrix (ECM) degrading enzymes, 
migration along collagen fibers [8] or nerve fibres [9], or 
collective migration in strands, sheets, or clusters. Most tu-
mors are of epithelial origin, and epithelial cells are typically 
non-motile and do not secrete ECM-degrading enzymes, 
which is the hallmark of invasive cells. Thus, to acquire the 
ability to migrate and degrade ECM, cells can undergo an 
epithelial-mesenchymal transition (EMT). Epithelial cells that 
convert to a mesenchymal phenotype lose their apical-basal 
polarization, and thus their ability to adhere to neighbo-
uring cells, acquire a spindle shape, and potential to secrete 
metalloproteinases [10]. EMT is triggered by transcription 
factors, such as SNAIL, SLUG, ZEB, KLF8, or Twist. During 
the process of EMT, the expression of proteins specific for 
epithelial cells (e.g., E-cadherin, cytokeratins and EpCAM) 
decreases, whereas expression of proteins characteristic 
for mesenchymal cells (e.g., vimentin and N-cadherin) in-
creases. The ability to penetrate the basement membrane 
and extracellular matrix also increases. These are widely 
regarded as metastasis-promoting factors. However, the 
exact role of EMT in cancer dissemination is currently under 
debate. This is because, although EMT undeniably renders 
cells more motile and invasive, supports their survival in 
the bloodstream and protects them from anoikis (a form 
of apoptosis triggered by the lack of adhesion), several 
recent reports suggest that it is dispensable for metasta-
sis — especially in breast and pancreatic cancers [11, 12]. 
It is also worth recalling that, to efficiently colonize a new 
metastatic site, cancer cells must reverse EMT and undergo 
the mesenchymal-epithelial transition (MET). This reversal 
further complicates the process.
Other than the mesenchymal and collective mode of 
migration used by cancer cells to spread, there is also ame-
boid cell migration, which is faster than the other types of 
migration and is adhesion-independent. Ameboid cells do 
not degrade ECM, but rather, squeeze through the ECM 
structures or cracks in cell layers. Ameboid migration also 
requires substantial phenotypic changes, usually in the form 
of a mesenchymal-ameboid transition (MAT). 
In contrast to such modes of migration, collective move-
ment of cancer cell clusters do not require extensive pheno-
type changes, since they retain the principal property of epi-
thelial cells, which is the presence of strong cell-cell contacts. 
Presumably, this gives cancer cells an advantage in efficient 
seeding, given that they have been shown to have higher 
metastatic potential than single CTCs [13]. Indeed, polyclonal 
metastases have been documented in prostate cancer, and 
in mouse models of breast cancer [13, 14]. Although CTC 
clusters retain cell-cell contacts, studies have shown that they 
are not fully epithelial, but rather, display a hybrid epithelial-
-mesenchymal phenotype [13, 15]. This hybrid phenotype 
may be crucial to their metastatic efficiency.
CTC mobilization by treatment
A comprehensive review by Martin at al. [16] summa-
rizes the current knowledge on the effects of anti-cancer 
treatment on mobilization of CTCs into the circulation. It 
was shown that different types of treatment applied to 
cure locoregional disease (i.e., radiotherapy, surgery, sys-
temic therapies) may actually contribute to the increase 
in the number of CTCs in patients’ blood, or an increase in 
proliferative capacity of CTCs. One possible explanation of 
this finding is the detrimental effect of various anti-tumor 
therapies on tumor vasculature, which may facilitate the 
entry of cancer cells into the circulation. So far, no studies 
have proved that this effect impacts metastasis in patients, 
but certainly such an opportunity exists. Indeed, there are 
studies of metastasis in irradiated versus non-irradiated mice 
that point to this conclusion [17, 18]. As addressed later in 
this review, such effects may interfere with assessing the 
prognostic powers of CTC count in patients, which should 
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be taken into consideration. Further understanding of this 
topic may be critically important for deciding on treatment 
options, especially adjuvant therapies.
In the circulation
Hematogenous dissemination encompasses intrava-
sation of cancer cells and their survival in the bloodstream. 
Intravasation is promoted by a number of factors, including 
crosstalk in secretion between tumor cells and perivas-
cular macrophages, TGF-b signaling, and the expression 
of Twist [19]. Following intravasation, cancer cells expose 
themselves to an extremely hostile environment and are 
exposed to many potentially damaging agents, such as 
shear forces, lack of adhesion, the innate immune response, 
and oxidative stress. As such, it is not surprising that survival 
of cancer cells in the bloodstream (or lymphatic system) is 
minimal. However, cancer cells have devised some forms of 
protection, including EMT and association with platelets, 
which shields them from both immune attack and hemo-
dynamic shear forces. Platelets release TGF-b, inducing EMT 
[20], and they also secrete adenine nucleotides which relax 
endothelial cell junctions, which supports extravasation [21]. 
CTCs also undergo reversible metabolic changes, which 
helps them to withstand oxidative stress [22].
CTC flow is determined by patterns of blood circulation. 
This may help to explain why the lungs and liver are some 
of the most common target sites of metastasis, due to the 
venous circulation from most organs and the gut. Extravasa-
tion is thought to occur by mechanical entrapment of CTCs 
in capillaries and rupture of these vessels [23]. This mecha-
nism could be especially effective for CTC clusters, when 
considering their size. CTC clusters were recently shown, 
however, to traverse capillary vessels, thereby reversibly 
re-organizing into a single-chain structure [24]. These data 
demonstrate that not all CTCs will end up being lodged 
within a capillary vessel. Rather, CTCs can extravasate by 
adhering to the vascular wall, and transmigrating to the 
other side of the endothelial cell layer. 
Seeding
Infiltrating new tissue is the next and very inefficient 
step in cancer cell dissemination. Although CTCs extrava-
state and became DTCs, their chance of survival depends 
on the supportive metastatic niche in which they can pro-
liferate, or at least survive and stay dormant. The creation 
of a pre-metastatic niche, even before the arrival of tumor 
cells, is promoted by factors secreted by the primary tumor 
(i.e., cytokines, growth factors, exosome components). The-
se travel via the circulation to distant organs, and initiate 
structural and functional changes at a new site, which pri-
marily encompass modifications to ECM components (i.e., 
fibronectin, tenascin C, collagens, galectins, periostin, oste-
opontin, versican, lysyl oxidase, MMPs) and the recruitment 
of bone marrow-derived cells [25]. Pre-metastatic changes 
create a permissive microenvironment, and allow some of 
the tumor cells to survive after extravasation. Nevertheless, 
a substantial proportion of tumor cells remain dormant. 
Further changes (e.g., immune, hormonal, or growth fac-
tor activation) may induce proliferation of these cells and 
produce macrometastasis. 
Clinical application
To date, the only test approved by the FDA for measuring 
CTCs is the CellSearch system (Veridex, USA). Defined criteria 
for measuring CTCs and clinical study outcomes have led to 
the inclusion of the CellSearch test as a prognostic tool for bre-
ast cancer [26, 27], colorectal cancer [28], and prostate cancer 
[29] in advanced stages of metastatic cancer. The number of 
preclinical and clinical studies on the possible applications of 
CTCs continues to grow, and studies have been conducted on 
both early stage disease and advanced cancer. These studies 
have focused primarily on using the CellSearch platform with 
RT-PCR. However, to date, no system based on CTCs has been 
approved to guide the appropriate choice of treatment and 
to monitor treatment efficacy. This may be because studies 
evaluating CTCs are often difficult to interpret, which may be 
due to various factors, including: different techniques for me-
asuring CTCs, different criteria for defining CTCs (expression 
of various tumor markers), heterogeneity among enrolled 
patients, or a limited number of patients meeting required 
enrollment criteria. At present, the only FDA-approved cli-
nical application of CellSearch is in estimating the chances 
of disease progression and/or survival. Indeed, the majority 
of research studies, including those reviewed by the FDA, 
confirm the prognostic value of CTCs for estimating clinical 
parameters, such as disease-free survival (DFS), overall survi-
val (OS), and progression-free survival (PFS).
CTCs as a prognostic factor: measurement of CTCs 
prior to treatment, and monitoring CTC levels 
after initiation of therapy
Breast cancer
A landmark study by Cristofanilli et al. demonstrated 
that the amount of blood CTCs (measured by CellSearch) in 
women with metastatic breast cancer prior to the start of 
a new therapy differentiated patients at high vs low risk of 
rapid progression [26]. The cut-off point between the two 
groups was set at 5 CTC per 7.5 mL of peripheral blood. Other 
studies, with 75 patients have shown that this established 
cut-off point is also predictive of PFS and OS. Further studies 
have confirmed the prognostic value of CTCs, suggesting 
that it is possible to assess progression rates prior to under-
taking antitumor therapy in patients with metastasis to di-
stant organs [27, 30, 31]. Taken together, these encouraging 
results provide the basis of further research for using CTCs 
in qualifying patients to more invasive therapies.
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Prostate cancer 
A study on 231 patients with prostate cancer resistant 
to castration (CRPC) with distant metastases has shown the 
prognostic value of CTCs, according to OS rates [32]. This 
study contributed to the acceptance of CellSearch by the 
FDA for this group of patients [32]. In this study, elevated 
CTC levels (i.e. ≥ 5 CTCs/7.5 mL blood) measured by an assay 
prior to chemotherapy was associated with poorer OS than 
in patients who had CTC levels < 5. This association has also 
been observed after the initiation of therapy. Survival was 
significantly longer among patients with CTC levels below 
the cut-off level, relative to patients with persistently high 
CTCs. For patients with CTC levels that increased in the 
follow-up to ≥ 5 CTCs, OS was poorer compared to patients 
with persistently low levels (< 5 CTCs). This may be due to 
the resistance of the subpopulation of cancer cells to the 
applied treatment. Taken together, these results indicate 
that continual assessment of CTCs during therapy may allow 
for closer evaluation of treatment efficacy and/or a better 
survival profile than a single assessment of CTCs prior to 
treatment.
To confirm these assumptions, two clinical trials are 
currently underway through the Stand Up to Cancer and 
the Prostate Cancer Foundations [33]. These studies aim 
to evaluate the potential for changing levels of CTCs in 
the blood during therapy to predict disease course among 
patients with prostate cancer.
Colorectal cancer 
One study used the CellSearch system to confirm distant 
metastases in 430 colorectal cancer patients undergoing 
chemotherapy [28]. Using an estimated cut-off point of 
3 CTCs/7.5 mL blood, the authors found that CTCs showed 
prognostic value for both PFS and OS. As with the study on 
prostate cancer [32], a decrease in CTCs below the cut-off 
point after chemotherapy was associated with significan-
tly longer PFS and OS, compared with rates observed in 
patients with persistently high CTCs. A study by Molnar et 
al. in colorectal cancer patients treated with chemothera-
py reported a significantly higher number of single CTCs, 
doublets, and CTC clusters in treatment non-responders 
relative to responders [34]. Moreover, in the study by Molnar 
et al., higher levels of CTCs correlated with macroscopic 
progression [34].
CTC as a substitute endpoint in clinical trials
When planning clinical trials, endpoints are defined. 
Endpoints are variables that determine patient health status 
for those taking part in the trial, and may include: survival, 
death, quality of life (rating in scores), or myocardial infarc-
tion. Instead of endpoints, surrogate endpoints may be used. 
Surrogate endpoints may be indicators of physiological or 
pathological processes (e.g., blood pressure levels), and are 
also called ‘biomarkers’ [35]. CTCs as a potential surrogate 
endpoint may be beneficial may be useful for predicting 
disease progression in early and late stages of cancer, mo-
nitoring response to treatment, or minimizing molecular 
residual disease after therapy. Several clinical studies on the 
efficacy of anti-cancer therapy have evaluated CTCs as a po-
tential surrogate endpoint. For example, one study found 
that measuring CTCs via the CellSearch system was more 
sensitive than radiological imaging as a prognostic factor 
among patients with advanced breast cancer [36]. Further, 
the authors found an association between high and persi-
stent levels of CTCs and a shorter OS, whereas radiological 
scans showed no disease progression [36]. Based on these 
results, the authors concluded that CTCs may indeed be 
a superior surrogate endpoint measure, as they are highly 
reproducible and correlate more closely with OS than do 
changes determined via traditional radiology.
In another study, CTC levels reportedly predicted disease 
progression at 9–12 weeks after the initiation of therapy 
among patients with advanced breast cancer [37]. This tech-
nique is therefore more precise than FDG-PET and CT, and 
predicted disease progression when radiographic imaging 
had little prognostic value for patients with CTC levels below 
the threshold level of 5/7.5 mL blood. Yet another study 
found that CTC levels measured early, prior to diagnostics 
(i.e., at 7–9 weeks) were strongly correlated with subsequ-
ent radiographic images [31]. Taken together, these results 
suggest that CTCs may be used together with radiographic 
imaging to evaluate response to therapy. However, for CTCs 
to be considered a reliable endpoint in clinical trials, further 
research is needed in this area. There is also a need for more 
accurate validation of the selected method for measuring 
these cells in a particular patient test group. 
CTCs for assessing effectiveness  
of the applied therapy 
Prognostic properties of CTCs measured by the Cell-
Search method have been used to further study how specific 
therapies may be selected. For example, therapies may be 
selected based on baseline levels of CTCs in the blood prior 
to therapy, or based on changes in CTC numbers during 
therapy.
These possibilities are currently being studied on a large 
scale in patients with metastatic breast cancer, through 
the SWOG S0500 trial (American South West Oncology 
Group) [38]. The purpose of the SWOG S0500 trial is to con-
firm whether persistently high CTC numbers (≥ 5/7.5 mL 
blood) after the first chemotherapy cycle are an indicator 
of disease progression and/or for a change in treatment 
strategy. The assumption is that unchanged blood levels of 
CTCs reflect cancer cell resistance to the adopted therapy. 
Therefore, patients with persistently high CTCs should shift 
to another treatment, whereas patients with changing levels 
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should continue the current therapy. This strategy thus al-
lows for assessment of whether early referral to alternative 
therapy improves OS and PFS. Unfortunately, however, pre-
liminary phase III results are not as promising as expected. 
Although results have confirmed the prognostic value of 
CTCs after the first cycle of chemotherapy in predicting OS, 
they did not show clinical value for evaluating the effective-
ness of therapy. Given that patients continued their therapy 
that was initiated prior to qualifying for the SWOG S0500 
study, it was not possible to exclude the effect of therapy 
on CTCs in the blood. The effect of various therapies on 
CTCs has not yet been defined, and the available literature 
data are not consistent in this regard [31]. It is possible that 
after the first treatment cycle, it is too early to assess CTC 
fluctuations concerning treatment efficacy. 
Another recently initiated study in this group of patients 
is the CirCe01 study, which is evaluating changes in CTCs 
(measured by CellSearch) as early resistance markers after 
the initiation of therapy [39]. Upon observing persistently 
high CTC levels after the third cycle of chemotherapy, some 
patients will be directed to an alternative treatment. After 
the first cycle of an alternative therapy, CTCs will again be 
monitored, and upon reaching ≥ 5 CTCs/7.5 mL of blood, 
patients will be redirected to yet another therapy. The pre-
mise of this study is to establish whether early detection of 
chemoresistance is possible by measuring CTCs in the blood. 
There is however, a risk that a too rapid interruption of targe-
ted anti-cancer therapy will stimulate the biological activity 
of some cancer cell subpopulations, and that introducing 
alternative therapies will not yield the expected benefits. 
Additionally, to establish an effective antineoplastic 
therapy, clonal evolution of cancer cells should be charac-
terized by means of CTC phenotype features. Expression 
of tumor markers (e.g., ER, PG, HER2) may vary between 
primary tumor cells and distant metastases in breast cancer 
[40, 41]. As a result, circulating blood cells with metastatic 
potential may provide a better genetic model for guiding 
appropriate therapy for a particular patient. The purpose 
of these studies is not only to identify patients who may 
benefit from a certain therapy, but also to discover the 
mechanisms responsible for cancer cells developing tre-
atment resistance and identifying appropriate therapeutic 
targets. One such study is the DETECT III study, which inc-
ludes patients with breast cancer without HER2 expression 
in the primary tumor, and at least one detected CTC cell 
expressing this receptor. The purpose of the DETECT III 
study is to determine the efficacy of lapatinib (an inhibitor 
of the tyrosine kinase receptors HER2 and EGFR) in a select 
group of patients [41].
Another strategy for choosing a therapy for advanced 
breast cancer is based on the CTC-Endocrine Therapy Index 
(CTC-ETI) test, which simultaneously measures CTCs in the 
blood and the expression of selected tumor markers (i.e., 
ER, BCL-2, HER2, Ki-67) that are predictors of resistance and 
sensitivity to endocrine therapy [42]. The CTC-ETI test aims 
to identify patients with estrogen receptor (ER) expression, 
for whom endocrine therapy may be ineffective. Validating 
the CTC-ETI test could in the future be used as a criterion 
for choosing an appropriate therapy (i.e., endocrine vs che-
motherapy) among patients with ER-positive breast cancer 
with distant metastases.
Several studies have found a correlation between the 
presence of CTCs and disease stage, among patients with 
primary colorectal cancer as well as patients with distant me-
tastasis. In these studies, CTCs were measured via CellSearch 
after tumor removal but before chemotherapy, and the cut-
-off point was ≥ 2 CTCs/7.5 mL of blood. The proportion of 
patients with CTCs ranged from 5% to 25% at stages I–III, and 
62% at distant metastasis stage [43, 44]. One study showed 
no CTCs after surgery among patients at stages I–III using 
the same cut-off point [45]. An interesting correlation was 
found in a homogeneous but small group of 37 patients at 
stage II and III, such that CTC levels were higher in patients at 
high risk relative to lower risk patients of the same stage [46]. 
These results highlight the potential use of CTCs among 
patients with metastatic colorectal cancer. Specifically, CTCs 
may be useful for guiding the application of more or less 
aggressive therapy for stage III, and introducing adjuvant 
chemotherapy for high risk stage II patients. 
CTCs in localized tumors  
without distant metastases
Thus far, the study outcomes when using CTCs in pa-
tients with stage I–III breast cancer have not been clear in 
terms of the number of detectable CTCs. However, these 
studies do suggest that measuring CTCs before and during 
therapy may be an additional factor predicting risk of local 
disease relapse, and can be measured in addition to more 
commonly assessed biomarkers (i.e., tumor size, lymph node 
involvement, HER2 amplification). Consequently, CTCs may 
be of clinical relevance in the early detection of residual 
disease. Consistent with this notion, one study demonstra-
ted that CTCs with CK19 expression (as detected by RT-PCR 
measured mRNA levels) are an independent predictor of PFS 
and OS among patients with both involved and clear lymph 
nodes [47]. These results were subsequently confirmed in an 
independent study of 167 patients with uninvolved lymph 
nodes undergoing chemotherapy [48]. CTCs were monito-
red in 23 mL of peripheral blood in the German SUCCESS 
study, which includes 1,500 patients with metastatic and 
non-metastatic breast cancer at high risk and treated with 
chemotherapy. In that study, they found a correlation be-
tween the presence of ≥ 1 CTC/23 mL of blood before che-
motherapy and the number of lymph nodes involved, and 
detection of ≥ 1 CTC during chemotherapy subsequently 
predicted DFS and OS [32]. In another study of 404 patients 
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undergoing tumor resection, the presence of CTCs prior to 
surgical intervention was associated with a slightly higher 
likelihood of local recurrence (78.9% for a 4-year period 
without recurrence) compared to patients without CTCs 
(88.4%) [49]. However, the small difference in outcomes 
between groups and the occurrence of metastases among 
patients without CTCs do raise some concerns about whe-
ther the CellSearch method can be used for determining 
the risk of recurrence for this group of patients.
Clinical application of CTCs: Summary
The lack of prospective studies on a homogenous and 
large group of patients together with the lack of knowledge 
about the effects of different therapies on CTC rates, preclu-
de us from assessing whether a clinical application of CTCs is 
possible. When examining these applications among breast 
cancer patients, it appears to be particularly important that 
patients are adequately stratified according to their cancer 
subtypes. In 2017, the first European statistical analysis of the 
potential predictive value by CellSearch was published [50]. 
The analysis included 1,944 patients with metastatic breast 
cancer, from 51 centers. Using the cut-off threshold of 5 
CTCs/7.5 mL blood, results clearly indicated that detection of 
CTCs — both before and during treatment — was associated 
with worse prognosis. Furthermore, CTCs measured prior 
to any new treatment constitute independent prognostic 
markers that could supplement the currently used clinical 
predictive biomarkers of breast cancer. It is also noteworthy 
that predicted disease progression was more accurate when 
based on measurement of CTC levels after the initiation of 
therapy, compared to predictions based on levels of tumor 
markers recommended for monitoring metastatic breast 
cancer according the international guidelines (e.g., CEA, 
CA15-3) [51]. This is the first analysis carried out in a large 
group of patients in Europe, and demonstrates the utility 
of CTCs in monitoring the progression of distant metastatic 
breast cancer, and accurately determining the risk of disease 
progression in a given patient.
Perspective
CTCs are expected to be routinely used in the next ten 
years alongside other clinical methods and markers (i.e., 
imaging techniques, serum markers) for tracking tumor 
growth over time [52]. We expect that fluid biopsy outcomes 
from a patient’s blood obtained via modern and automated 
methods will enable the clinician to detect the cancer, de-
termine its severity, and establish therapeutic goals. These 
outcomes will also allow for more personalized and modi-
fiable treatments, based on the qualitative and quantitative 
monitoring of CTCs [53]. Moreover, more in-depth molecular 
research on CTCs broadens the knowledge-base on the 
biology of metastasis, which also has important implications 
for treating cancer patients.
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